The THRombolysis and STatins (THRaST) study

Manuel Cappellari, Paolo Bovi, Giuseppe Moretto, Andrea Zini, Patrizia Nencini, Maria Sessa, Mauro Furlan, Alessandro Pezzini, Giovanni Orlandi, Maurizio Paciaroni, Tiziana Tassinari, Gaetano Procaccianti, Vincenzo Di Lazzaro, Luigi Bettoni, Carlo Gandolfo, Giorgio Silvestrelli, Maurizia Rasura, Giuseppe Martini, Maurizio Melis, Maria Vittoria CalloniFabio Chiodo-Grandi, Simone Beretta, Maria Guarino, Maria Concetta Altavista, Simona Marcheselli, Giampiero Galletti, Laura Adobbati, Massimo Del Sette, Armando Mancini, Daniele Orrico, Serena Monaco, Anna Cavallini, Rossella Sciolla, Francesco Federico, Umberto Scoditti, Fabio Brusaferri, Claudio Grassa, Luigi Specchio, Maria Roberta Bongioanni, Marco Sparaco, Mauro Zampolini, Gabriele Greco, Rinaldo Colombo, Bruno Passarella, Alessandro Adami, Domenico Consoli, Danilo Toni

Research output: Contribution to journalArticle

Abstract

Objective: To assess the impact on stroke outcome of statin use in the acute phase after IV thrombolysis. Methods: Multicenter study on prospectively collected data of 2,072 stroke patients treated with IV thrombolysis. Outcome measures of efficacy were neurologic improvement (NIH Stroke Scale [NIHSS] ≤ 4 points from baseline or NIHSS = 0) and major neurologic improvement (NIHSS ≤ 8 points from baseline or NIHSS = 0) at 7 days and favorable (modified Rankin Scale [mRS] ≤ 2) and excellent functional outcome (mRS ≤ 1) at 3 months. Outcome measures of safety were 7-day neurologic deterioration (NIHSS ≥ 4 points from baseline or death), symptomatic intracerebral hemorrhage type 2 with NIHSS ≥ 4 points from baseline or death within 36 hours, and 3-month death. Results: Adjusted multivariate analysis showed that statin use in the acute phase was associated with neurologic improvement (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.26-2.25; p <0.001), major neurologic improvement (OR 1.43, 95% CI 1.11-1.85; p = 0.006), favorable functional outcome (OR 1.63, 95% CI 1.18-2.26; p = 0.003), and a reduced risk of neurologic deterioration (OR: 0.31, 95% CI 0.19-0.53; p <0.001) and death (OR 0.48, 95% CI 0.28-0.82; p = 0.007). Conclusion: Statin use in the acute phase of stroke after IV thrombolysis may positively influence short- and long-term outcome.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalNeurology
Volume80
Issue number7
DOIs
Publication statusPublished - Feb 12 2013

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Fingerprint Dive into the research topics of 'The THRombolysis and STatins (THRaST) study'. Together they form a unique fingerprint.

  • Cite this

    Cappellari, M., Bovi, P., Moretto, G., Zini, A., Nencini, P., Sessa, M., Furlan, M., Pezzini, A., Orlandi, G., Paciaroni, M., Tassinari, T., Procaccianti, G., Di Lazzaro, V., Bettoni, L., Gandolfo, C., Silvestrelli, G., Rasura, M., Martini, G., Melis, M., ... Toni, D. (2013). The THRombolysis and STatins (THRaST) study. Neurology, 80(7), 655-661. https://doi.org/10.1212/WNL.0b013e318281cc83